Literature DB >> 2869209

Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease.

J A Obeso, M R Luquin, J M Martínez-Lage.   

Abstract

Intravenous levodopa or lisuride infusions can successfully reduce daily motor fluctuations in Parkinson's disease, which indicates adequate striatal dopaminergic mechanisms even in severe cases. In 3 patients who received continuous subcutaneous administration of lisuride, by means of a portable mini-infusion pump, in addition to oral levodopa plus decarboxylase inhibitor, mobility improved considerably and "off" periods were reduced or abolished. This response was maintained for 4 to 7 months without toxic side-effects, but increased dyskinetic movements were observed. All 3 patients were discharged and have been able to live independently during the months on treatment. These results suggest that continuous dopaminergic stimulation with the use of a portable delivery system can be a practical therapeutic tool in parkinsonian patients with complicated motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869209     DOI: 10.1016/s0140-6736(86)92929-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  16 in total

Review 1.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

Review 2.  A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 3.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

4.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

5.  Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in parkinsonian squirrel monkeys.

Authors:  N M Rupniak; S J Tye; C A Jennings; A E Loper; J V Bondi; M Hichens; S D Iversen; S M Stahl
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

6.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 7.  Dystonia in Parkinson's disease.

Authors:  Eduardo Tolosa; Yaroslau Compta
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 8.  Treatment of Parkinson's disease.

Authors:  M J Aminoff
Journal:  West J Med       Date:  1994-09

9.  Continuous subcutaneous lisuride infusion in OPCA.

Authors:  A Heinz; J Wöhrle; L Schöls; P Klotz; W Kuhn; H Przuntek
Journal:  J Neural Transm Gen Sect       Date:  1992

10.  Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?

Authors:  K A Muhiddin; M T Roche; V R Pearce
Journal:  Postgrad Med J       Date:  1994-05       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.